Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA
Sign Up to like & getrecommendations! Published in 2018 at "ChemMedChem"
DOI: 10.1002/cmdc.201700666
Abstract: Herein we report the first exploration of a dual‐targeting drug design strategy to improve the efficacy of small‐molecule cancer immunotherapy. New hybrids of indoleamine 2,3‐dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target… read more here.
Keywords: dual targeting; ido1 dna; cancer immunotherapy;